APIIC's Brian Doty says key starting materials are where domestic generic supply efforts must focus, and continuous flow chemistry makes the business case.

How the midterm results stall Trump’s MFN push, and why differential pricing, compulsory licensing and transparency dominate the WHO Fair Pricing Forum.

Bob Cochran, former senior director, trade relations at Incyte, discusses direct-to-patient models, specialty launches and ...

A CMS final rule codifies Medicare drug price negotiation from 2029, adds a fixed combination drug policy and implements a small biotech price floor.

Generative AI has made pharma teams faster, but real value depends on redesigning commercialization workflows, especially as ...

Pharmaceutical Commerce connects biopharma executives to insights on business processes, technologies, and strategies for taking approved drugs to market.

Siloed pricing, contracting and affordability decisions can undercut a launch. IQVIA experts explain how system-level modeling surfaces trade-offs early. Market access teams can make individually ...

Nuvera’s PURE Engagement research, built on feedback from more than 2,300 physicians and support staff, ranks 2026 patient ...

Specialty distribution and provider platforms drove September-quarter profit gains at the Big Three as brand pricing weighed on results.